Siemens Healthineers Shares: A Study's Promise Meets Market Pessimism

Jefferies maintains a buy rating with a €60 target as landmark software validation contrasts with stock near 52-week lows. Q2 results on May 7 are the next key catalyst.

While Siemens Healthineers showcased a significant clinical validation last Sunday, its stock performance continues to reflect broader market concerns, creating a stark contrast between technological progress and investor sentiment.

Jefferies Maintains Bullish Stance Amid Challenges

On March 24, the research firm Jefferies reaffirmed its buy recommendation for Siemens Healthineers, holding a price target of 60 euros. This represents a potential upside of nearly 70 percent from the current trading level of approximately 35.92 euros, highlighting a substantial gap between the market's valuation and the analyst's assessment.

Jefferies acknowledged that near-term organic revenue growth and profit margins might fall slightly below long-term trends. However, the analysts view geopolitical headwinds, including tensions involving Iran and rising energy costs, as largely manageable for the company. They cite Siemens Healthineers' global operational footprint as a natural buffer against regional instability.

Landmark Validation for a Software-Driven Strategy

The focal point of the recent announcement was data from the FAST-III study, presented at the American College of Cardiology congress. The research, conducted across 37 hospitals in seven countries with 2,235 patients, validated the company's Caas vFFR software.

This technology calculates blood flow in coronary arteries using just two X-ray images, eliminating the need for a physical pressure wire—an invasive procedure associated with higher risks and costs. The study confirmed the software-based method as an equivalent diagnostic alternative.

The implications are substantial. By reducing the need for consumable materials and invasive interventions while maintaining diagnostic quality, the software presents real potential for hospitals to lower operational costs. For Siemens Healthineers, this successful validation reinforces its strategic pivot from a hardware-centric model toward software solutions and digitalized clinical workflows.

Market Performance and Upcoming Catalyst

Despite this positive development, the equity trades just above its 52-week low and remains about 28 percent below its peak from April 2025. The market now awaits the company's second-quarter results, scheduled for release on May 7. Investors generally expect Siemens Healthineers to reaffirm its annual targets during this update. Whether that confirmation will be sufficient to catalyze a sustained recovery in the share price remains the critical question for the coming weeks.